Naldemedine

Contraindicated

Naldemedine Ensitrelvir Increased CYP3A/P-gp substrate exposure and an increased risk of adverse reactions Details

Major

Naldemedine Abametapir Increased exposure of CYP3A4 substrate Details Naldemedine Alvimopan Entereg Increased risk of opioid withdrawal Details Naldemedine Capmatinib Tabrecta Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Naldemedine Lenacapavir Injection Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Naldemedine Lenacapavir Oral Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Naldemedine Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Naldemedine Methylnaltrexone Relistor Increased risk of opioid withdrawal Details Naldemedine Methylnaltrexone Injection Relistor Increased risk of opioid withdrawal Details Naldemedine Apalutamide Erleada Reduced P-gp/CYP3A4 substrate exposure Details Naldemedine Avacopan Tavneos Increased CYP3A4 substrate exposure Details Naldemedine Berotralstat Orladeyo Increased P-gp substrate exposure Details Naldemedine Clarithromycin Biaxin Increased exposure of CYP3A4 substrate and risk for toxicity Details Naldemedine Conivaptan Vaprisol Increased CYP3A substrate exposure Details Naldemedine Erythromycin Erythrocin Stearate Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Naldemedine Fedratinib Inrebic Increased CYP3A4 substrate exposure Details Naldemedine Fexinidazole An increased CYP3A4 substrate exposure Details Naldemedine Itraconazole Sporanox Increased CYP3A4/P-gp substrate exposure and an increased risk of CYP3A4/P-gp substrate-related adverse effects Details Naldemedine Lenacapavir Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Naldemedine Letermovir Prevymis Increased CYP3A substrate exposure Details Naldemedine Mifepristone Korlym Increased CYP3A4 substrate exposure Details Naldemedine Nalorphine Increased risk of opioid withdrawal Details Naldemedine Naloxone Kloxxado Increased risk of opioid withdrawal Details Naldemedine Naltrexone ReVia Increased risk of opioid withdrawal Details Naldemedine Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Naldemedine Phenobarbital Fidoquel Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Naldemedine Primidone Mysoline Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Naldemedine Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Naldemedine Samidorphan Increased risk of opioid withdrawal Details Naldemedine Tazemetostat Tazverik Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Naldemedine Venetoclax Venclexta Increased exposure of P-gp substrate and an increased toxicities of these substrates Details Naldemedine Vimseltinib Romvimza Increased risk of P-gp substrate exposure Details Naldemedine Voriconazole Vfend Increased CYP3A4 substrates exposure and an increased efficacy of CYP3A4 substrates-related adverse effects Details Naldemedine Naloxone Injection Evzio® Increased risk of opioid withdrawal Details Naldemedine Naloxone Nasal Spray Kloxxado Increased risk of opioid withdrawal Details

Moderate

Naldemedine Artemether Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Naldemedine Carbamazepine Carbatrol Reduced naldemedine exposure and decreased efficacy Details Naldemedine Enzalutamide Xtandi Reduced naldemedine exposure and decreased efficacy Details Naldemedine Fosphenytoin Cerebyx Reduced naldemedine exposure and decreased efficacy Details Naldemedine Kratom Increased CYP3A substrate exposure Details